{"id":"cemiplimab-plus-regn3767","safety":{"commonSideEffects":[{"rate":"20%","effect":"Fatigue"},{"rate":"15%","effect":"Rash"},{"rate":"10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4297723","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"REGN3767, also known as cemiplimab, is a human monoclonal antibody that targets the programmed death receptor-1 (PD-1). By blocking PD-1, cemiplimab enhances the immune system's ability to detect and destroy cancer cells.","oneSentence":"Cemiplimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, enhancing T-cell activation and immune response against tumor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:31.800Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 ≥50%"},{"name":"Cutaneous squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT06769698","phase":"PHASE2","title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":120},{"nctId":"NCT07281768","phase":"PHASE2","title":"Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-04","conditions":"Colorectal Cancer","enrollment":66},{"nctId":"NCT06205836","phase":"PHASE2","title":"Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-06-13","conditions":"Colorectal Cancer","enrollment":44},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06918132","phase":"PHASE2","title":"Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-29","conditions":"Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":60},{"nctId":"NCT06246916","phase":"PHASE3","title":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-09","conditions":"Melanoma","enrollment":560},{"nctId":"NCT06787612","phase":"PHASE2","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-05-28","conditions":"Ovarian Cancer","enrollment":220},{"nctId":"NCT06190951","phase":"PHASE2","title":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-18","conditions":"Melanoma","enrollment":151},{"nctId":"NCT04989946","phase":"PHASE1, PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT05800015","phase":"PHASE2, PHASE3","title":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-08-08","conditions":"Non-small Cell Lung Cancer","enrollment":950},{"nctId":"NCT05785767","phase":"PHASE2, PHASE3","title":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-06-30","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":850},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT06848088","phase":"PHASE2","title":"A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-04-14","conditions":"Melanoma","enrollment":48},{"nctId":"NCT06161441","phase":"PHASE2","title":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-16","conditions":"Resectable Non-small Cell Lung Cancer","enrollment":195},{"nctId":"NCT05352672","phase":"PHASE3","title":"Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-07-14","conditions":"Melanoma","enrollment":1546},{"nctId":"NCT06571708","phase":"PHASE2","title":"Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-08-14","conditions":"Bladder Cancer, Muscle-Invasive Bladder Carcinoma","enrollment":36},{"nctId":"NCT04706715","phase":"PHASE1, PHASE2","title":"LAG3 PET Imaging in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2022-01-18","conditions":"Metastatic Solid Tumor","enrollment":41},{"nctId":"NCT05608291","phase":"PHASE3","title":"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-01-16","conditions":"Melanoma","enrollment":1564},{"nctId":"NCT06384820","phase":"PHASE2","title":"Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)","status":"WITHDRAWN","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-11-14","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03005782","phase":"PHASE1","title":"Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-11-07","conditions":"Malignancies","enrollment":333}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cemiplimab plus REGN3767","genericName":"Cemiplimab plus REGN3767","companyName":"QuantumLeap Healthcare Collaborative","companyId":"quantumleap-healthcare-collaborative","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cemiplimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, enhancing T-cell activation and immune response against tumor cells. Used for Non-small cell lung cancer, PD-L1 ≥50%, Cutaneous squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}